Analyst consensus rating
Ligand Pharmaceuticals Analyst Rating: Strong Buy
LGND is rated Strong Buy by 11 analysts with a $342.82 target. As of 2026-09-02.
Direct answer
Ligand Pharmaceuticals's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $342.82.
Forecast evidence checked September 2, 2026.
Get free Ligand Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $284.27
- Average price target
- $342.82
- High price target
- $390.00
- Low price target
- $247.00
- Low target gap
- -13.1%
- Target upside
- +20.6%
- High target gap
- +37.2%
- Target range width
- 50.3%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $342.82.
How far are Ligand Pharmaceuticals's low and high targets from the recorded price?
The low target implies -13.1%, while the high target implies +37.2%.
How many analysts are included in Ligand Pharmaceuticals's consensus?
The verified consensus includes 11 analysts.
How is Ligand Pharmaceuticals's target upside or downside calculated?
The average target of $342.82 is divided by the recorded price of $284.27, then one is subtracted to produce +20.6%. This does not guarantee a future return.
When was Ligand Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.